Sarepta Therapeutics Soars 16% in After-Hours Trading Following News of Potential Approval of SRP-9001 for Duchenne Muscular Dystrophy.
March 7, 2023
Trending News ☀️
Sarepta Therapeutics ($NASDAQ:SRPT) soared 16% in after-hours trading following news from the US FDA that an advisory committee would not be necessary for the Biologics License Application (BLA) of SRP-9001 for Duchenne muscular dystrophy (delandistrogene moxeparvovec). The FDA has set the action date for May 29, which could mean approval of the drug. The approval of SRP-9001 will be a major milestone in the treatment of Duchenne muscular dystrophy, a rare and devastating genetic disorder which is progressive and nearly always fatal.
Price History
At the time of writing, news coverage of the development had been mostly negative. However, on Tuesday SAREPTA THERAPEUTICS stock opened at $118.0 and closed at $122.1, up by 3.4% from the prior closing price of 118.1. This strong positive reaction indicates that investors are optimistic about the future of the company and the drug’s potential to treat this rare pediatric disorder. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Sarepta Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 933.01 | -703.49 | -67.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Sarepta Therapeutics. More…
| Operations | Investing | Financing |
| -325.35 | -1.05k | 232.51 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Sarepta Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.13k | 2.74k | 4.38 |
Key Ratios Snapshot
Some of the financial key ratios for Sarepta Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 34.8% | – | -68.2% |
| FCF Margin | ROE | ROA |
| -38.2% | -97.6% | -12.7% |
Analysis
GoodWhale’s analysis of SAREPTA THERAPEUTICS‘ fundamentals shows that it is a high risk investment. Our Risk Rating tool takes into account aspects from the company’s income sheet, balance sheet, cashflow statement, and non-financial data to assess the level of risk associated with a particular stock. If you become a registered user of GoodWhale, you can use our platform to monitor the 4 risk warnings that our system has detected for SAREPTA THERAPEUTICS. This will help you make a more informed decision about investing in the company. More…
Peers
The company is headquartered in Cambridge, Massachusetts and was founded in 1980. Sarepta Therapeutics Inc has four main competitors: Genor Biopharma Holdings Ltd, Impel Pharmaceuticals Inc, Entera Bio Ltd, and PTC Therapeutics Inc. These companies are all focused on the development of treatments for DMD and other rare diseases.
– Genor Biopharma Holdings Ltd ($SEHK:06998)
Genor Biopharma Holdings Ltd is a pharmaceutical company that focuses on the development and commercialization of innovative drugs for the treatment of cancer. The company has a market cap of 949.11M as of 2022 and a ROE of -23.99%. The company’s products are designed to target specific genetic mutations that are known to drive the growth and progression of cancer.
– Impel Pharmaceuticals Inc ($NASDAQ:IMPL)
Impel Pharmaceuticals Inc is a pharmaceutical company with a market cap of 94.72M as of 2022. The company has a Return on Equity of -359.89%. Impel Pharmaceuticals Inc is a company that focuses on the development and commercialization of drugs for the treatment of central nervous system disorders.
– Entera Bio Ltd ($NASDAQ:ENTX)
Entera Bio Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of oral therapeutics for serious unmet medical needs. The company’s lead product candidate is EB614, an oral biologic that is in clinical development for the treatment of osteoporosis, inflammatory bowel disease, and other immune-mediated diseases. Entera Bio Ltd has a market cap of 24.06M as of 2022, a Return on Equity of -48.6%. The company’s focus on the development and commercialization of oral therapeutics makes it a unique player in the biopharmaceutical market. However, its negative ROE indicates that it is not a profitable company at this time.
Summary
Sarepta Therapeutics saw a 16% surge in after-hours trading following news of potential approval of its drug SRP-9001 for Duchenne Muscular Dystrophy. Despite negative news coverage, the stock price jumped on the news, indicating that investors are still confident in the company moving forward. Investors should take note of Sarepta Therapeutics’ potential and take advantage of the current surge in stock price.
Sarepta Therapeutics is a biopharmaceutical company focused on treating rare diseases, and its recent drug approval offers a promising outlook for the company’s products and services moving forward. Although there is some uncertainty due to negative news coverage, investors should consider Sarepta Therapeutics as a potential investment opportunity.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
